MX2020006131A - Linfocitos infiltrantes de medula especificos para cancer de prostata y usos de los mismos. - Google Patents

Linfocitos infiltrantes de medula especificos para cancer de prostata y usos de los mismos.

Info

Publication number
MX2020006131A
MX2020006131A MX2020006131A MX2020006131A MX2020006131A MX 2020006131 A MX2020006131 A MX 2020006131A MX 2020006131 A MX2020006131 A MX 2020006131A MX 2020006131 A MX2020006131 A MX 2020006131A MX 2020006131 A MX2020006131 A MX 2020006131A
Authority
MX
Mexico
Prior art keywords
prostate cancer
infiltrating lymphocytes
cancer specific
marrow infiltrating
specific marrow
Prior art date
Application number
MX2020006131A
Other languages
English (en)
Spanish (es)
Inventor
Kimberly A Noonan
Ivan Borrello
Original Assignee
Windmil Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windmil Therapeutics Inc filed Critical Windmil Therapeutics Inc
Publication of MX2020006131A publication Critical patent/MX2020006131A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020006131A 2018-03-22 2019-03-22 Linfocitos infiltrantes de medula especificos para cancer de prostata y usos de los mismos. MX2020006131A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646649P 2018-03-22 2018-03-22
PCT/US2019/023543 WO2019183455A1 (en) 2018-03-22 2019-03-22 Prostate cancer specific marrow infiltrating lymphocytes and uses thereof

Publications (1)

Publication Number Publication Date
MX2020006131A true MX2020006131A (es) 2020-08-17

Family

ID=67986362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006131A MX2020006131A (es) 2018-03-22 2019-03-22 Linfocitos infiltrantes de medula especificos para cancer de prostata y usos de los mismos.

Country Status (11)

Country Link
US (1) US20210000876A1 (cg-RX-API-DMAC7.html)
EP (1) EP3735256A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021516666A (cg-RX-API-DMAC7.html)
KR (1) KR20200135936A (cg-RX-API-DMAC7.html)
CN (1) CN112074280A (cg-RX-API-DMAC7.html)
AU (1) AU2019240420A1 (cg-RX-API-DMAC7.html)
CA (1) CA3084179A1 (cg-RX-API-DMAC7.html)
IL (1) IL277482A (cg-RX-API-DMAC7.html)
MX (1) MX2020006131A (cg-RX-API-DMAC7.html)
SG (1) SG11202005200XA (cg-RX-API-DMAC7.html)
WO (1) WO2019183455A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037054A1 (en) * 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2022507113A (ja) * 2018-11-05 2022-01-18 ウィンドミル セラピューティクス インコーポレイテッド クローン性の増大した骨髄浸潤リンパ球およびそれらの使用
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
CN114072158A (zh) * 2019-03-22 2022-02-18 温德弥尔治疗公司 肺癌特异性骨髓浸润淋巴细胞及其用途
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
WO2017008019A1 (en) 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
GB201608918D0 (en) * 2016-05-20 2016-07-06 Aslan Pharmaceuticals Pte Ltd Method

Also Published As

Publication number Publication date
EP3735256A4 (en) 2021-10-13
CN112074280A (zh) 2020-12-11
KR20200135936A (ko) 2020-12-04
CA3084179A1 (en) 2019-09-26
JP2021516666A (ja) 2021-07-08
EP3735256A1 (en) 2020-11-11
SG11202005200XA (en) 2020-07-29
AU2019240420A1 (en) 2020-06-25
WO2019183455A1 (en) 2019-09-26
IL277482A (en) 2020-11-30
US20210000876A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CL2023000812A1 (es) Péptidos, combinaciones y andamiajes para uso en inmunoterapia contra el cáncer divisional de solic.2017-02448
CY1124977T1 (el) Αντισωματα anti-lag-3 για αγωγη αιματολογικων κακοηθειων
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
CL2023000708A1 (es) Péptidos y sus combinaciones para el uso en inmunoterapia contra el cáncer
CL2019002624A1 (es) Compuestos y métodos para la reducción celular específica.
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
ECSP17084270A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
MX2021015495A (es) Composiciones y métodos para tratar cáncer.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
MX385915B (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
BR112017020054A2 (pt) anticorpos para icos
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1